drugset
drugset / Trial / NCT00150709

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

NCT00150709 ↗

Phase 3 Completed 223 enrolled UCB Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.

Timeline

Start
1998-01-26
Primary completion
2006-01-25
Completion
2006-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified — Oral

Indications

focal epilepsy